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Secukinumab Provides Sustained Improvements in the
Signs and Symptoms of Psoriatic Arthritis: Final 5-year
Results from the Phase 3 FUTURE 1 Study
Philip J. Mease,1
Arthur Kavanaugh,2 Andreas Reimold,3 Hasan Tahir,4 Juergen Rech,5
Stephen Hall,6
7
8
8
9
Piet Geusens, Pascale Pellet, Eumorphia Maria Delicha, Luminita Pricop, Shephard Mpofu,8 and on behalf of
the FUTURE 1 study group
Objective. To report the 5-year efficacy and safety of secukinumab in the treatment of patients with psoriatic
arthritis (PsA) in the FUTURE 1 study (NCT01392326).
Methods. Following the 2-year core trial, eligible patients receiving subcutaneous secukinumab entered a 3-year
extension phase. Results are presented for key efficacy endpoints for the secukinumab 150-mg group (n = 236), including patients who escalated from 150 to 300 mg (approved doses) starting at week 156. Safety is reported for all
patients (n = 587) who received 1 dose or more of study treatment.
Results. Overall, 81.8%% (193 of 236) of patients in the secukinumab 150-mg group completed 5 years of
treatment, of which 36.4% (86 of 236) had dose escalation from 150 to 300 mg. Sustained improvements were
achieved with secukinumab across all key efficacy endpoints through 5 years. Overall, 71.0%/51.8%/36.3% of
patients achieved American College of Rheumatology (ACR) 20/50/70 responses at 5 years. Efficacy improved
in patients requiring dose escalation from 150 to 300 mg and was comparable with those who did not require
dose escalation. Exposure-adjusted incidence rates for selected adverse events per 100 patient-years for any
secukinumab dose were serious infections (1.8), Crohn’s disease (0.2), Candida infection (0.9), and major adverse
cardiac events (0.5).
Conclusion. Secukinumab provided sustained improvements in the signs and symptoms in the major clinical domains of PsA. Efficacy improved for patients requiring dose escalation from 150 to 300 mg during the study. Secukinumab was well tolerated with no new safety signals.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, inflammatory disease
characterized by peripheral arthritis, axial disease, dactylitis,
enthesitis, and skin and nail psoriasis (1,2). PsA can negatively
affect patients’ daily functioning and quality of life as a result of

permanent joint damage and disability (3). The reported prevalence of PsA in the general population is up to 1%, and it affects
around 30% of patients with psoriasis (2,4,5).
Biologic therapies, such as anti–tumor necrosis factor (TNF)
and anti–interleukin (IL)-17A antibodies, are recommended for
the treatment of PsA in patients who experience an inadequate
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response to first-line treatment with nonsteroidal anti-inflammatory
drugs (NSAIDs) and/or disease-modifying antirheumatic drugs
(DMARDs) (6–8). The proinflammatory cytokine IL-17A mediates multiple biological functions that result in joint and entheseal
inflammation and structural damage, which are characteristic of
PsA (9,10). Recommendations from the European League Against
Rheumatism (EULAR) (8) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (11) recognize
targeting IL-17A as a therapeutic strategy to manage all the main
clinical manifestations of PsA.
Secukinumab, a human monoclonal antibody that directly
inhibits IL-17A, provided rapid and significant improvements
in all key clinical manifestations of PsA in the FUTURE 1
study (NCT01392326) with improvements sustained through
3 years (12–14). These clinical benefits have been observed
in patients naïve to biologic therapy and in those with an
intolerance or inadequate response to agents targeting TNF
(3,8,9,11,13–16).
Data from FUTURE 1 have also shown that secukinumab significantly inhibits joint structural damage through 24 weeks (14),
with benefits sustained out to 3 years (3); it is worth noting that
radiographic data were only collected up to 3 years in this study
(3,17). Here, we present the final 5-year efficacy and safety results,
including efficacy results in patients who had a dose escalation
from 150 to 300 mg during the study.

METHODS
Study population. The study design of FUTURE 1 has
been described in detail elsewhere (3). In brief, the population of
the core study consisted of adults diagnosed with PsA, as classified by Classification Criteria for Psoriatic Arthritis (CASPAR)
criteria (18), and with moderate to severe symptoms for 6
months or more, who must have 3 or more tender joints of 78
and 3 or more swollen joints of 76 at baseline. Patients were
classed as anti-TNF inadequate responders (anti-TNF-IR) if they
had been taking an anti-TNF agent at an adequate dose for 3
months or longer, had experienced an inadequate response, or
had stopped treatment because of tolerability issues.
Clinical judgement of the investigator was used to assess
the suitability of a patient to enter the extension study based
upon overall improvement and response to therapy during the
core study. Only participants who had completed the 2-year
core study and had signed the new informed consent form were
included in the extension phase. Key exclusion criteria for the
extension included patients who were deemed not to be benefiting from the study treatment based upon lack of improvement
or worsening of their symptoms, patients receiving therapy with
biologic immunomodulation agents other than secukinumab,
and those with inflammatory disorders other than PsA, including
active ongoing inflammatory bowel disease (IBD), which might
confound the evaluation of therapy.
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Study oversight and design. This study was approved
by institutional review boards or ethics committees for each study
center and was conducted in accordance with the Declaration of
Helsinki. All patients provided written informed consent prior to
participation and again at the start of the extension study.
This extension study employed a parallel group, double-blind
design for the first year (up to and excluding week 156 [the 2-year
core study plus the first year of the extension study]), followed by
an open-label design for the next two years (week 156 onward).
Blinding during the first year of the extension study was required
to ensure that all patients had completed the core study and the
data was locked before unblinding occurred. Investigators used
their clinical judgment to decide if it was beneficial for patients to
enter the extension study based upon overall improvement and
response to therapy during the 2-year period of the core study.
At 2 years in the core study, eligible patients completed assessments and continued on the same dose as that received during the
core study (secukinumab at a dosage of 150 mg or 75 mg every
4 weeks). Study treatment dose adjustments were not permitted
until week 156. During the open label study period starting at week
156, the secukinumab dose could be escalated from 75 to 150 or
300 mg or from 150 to 300 mg for patients whose signs and symptoms were not fully controlled with the current dose as judged by the
investigator. Here, we report long-term results for the secukinumab
150-mg group, including patients who switched from placebo to
secukinumab 150 mg at weeks 16 or 24 following the end of the placebo-controlled period. We also report efficacy results for patients
who escalated from secukinumab 150 to 300 mg (approved doses).
For all patients who discontinued or withdrew from the study,
the investigator was to ensure that the patient completed an endof-treatment visit (corresponding to the last visit for the patient’s
current period of treatment) 4 weeks after last study treatment,
and also returned after an additional 8 weeks for a final follow-up
visit (12 weeks after last study treatment).
Endpoints and assessments. The primary endpoint of
this extension study was to evaluate the long-term efficacy of
secukinumab with respect to the proportion of patients achieving
20% or greater, 50% or greater, or 70% or greater improvement in
the American College of Rheumatology (ACR) criteria for improvement (ACR20, ACR50, and ACR70, respectively) over time, up
to 5 years in patients with active PsA who completed the core
study. ACR20/50/70 responses are reported for those patients
who were originally randomized to secukinumab 150 mg during
the core study to show the full 5-year efficacy and separately
for those who entered the extension study in the secukinumab
150 mg group (including patients both originally randomized
to secukinumab 150 mg and those switched from placebo to
secukinumab 150 mg at week 16 or 24).
Other assessments that continued for up to 5 years
included resolution of dactylitis and enthesitis, which were measured using the Leeds Dactylitis and Leeds Enthesitis Indices,
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Table 1. Demographics and baseline characteristics of patients
who entered the extension phase receiving secukinumab 150 mga
Secukinumab
150 mg (N = 236)

Characteristicb
Age (years)
Female, n (%)
Weight (kg)
BMI (kg/m2)
Time since first diagnosis of PsA (years)
Disease history and baseline characteristics
Anti–TNF-naïve, n (%)
Methotrexate use at randomization, n (%)
Systemic glucocorticoid use at
randomization, n (%)
Tender joint count (78 joints)
Swollen joint count (76 joints)
HAQ-DI
DAS28-CRP
Psoriasis (≥3% body surface area), n (%)
Presence of dactylitis, n (%)
Presence of enthesitis, n (%)

49.3 (11.57)
121 (51.3)
82.7 (19.70)
28.5 (6.47)
7.63 (7.927)
178 (75.4)
148 (62.7)
37 (15.7)
23.3 (16.90)
13.1 (10.25)
1.142 (0.667)
4.72 (1.079)
130 (55.1)
123 (52.1)
141 (59.7)

Abbreviation: BMI, body mass index; DAS28-CRP, Disease Activity
Score-28-C-reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; PsA, psoriatic arthritis; TNF, tumor necrosis
factor.
a
Baseline characteristics were recorded at baseline of the core study.
b
Results are mean (standard deviation) unless otherwise stated.

respectively; change from baseline in Health Assessment
Questionnaire-Disability Index (HAQ-DI); Short Form 36-item (SF36) health survey physical component summary (PCS); improvement (75% or greater and 90%) in Psoriasis Area and Severity
Index responses (PASI 75/90); change from baseline in Disease
Activity Score-28 (DAS28; utilizing high-sensitivity C-reactive
protein); the proportion of patients achieving low disease activity
(LDA) and disease remission based on DAS28 scores of 3.2 or
Week 104

14 Discontinued

• Adverse event (n=4)
• Lack of efficacy (n=3)
• Lost to follow-up (n=1)
• Pregnancy (n=1)
• Subject/guardian decision (n=5)

less and 2.6 or less, respectively, and the proportion of patients
achieving minimal disease activity (MDA; defined as having 5 out
of 7 of the following: 1 or fewer tender joint count, 1 or fewer
swollen joint count, PASI ≤ 1 or Investigator’s Global Assessment
[IGA] score ≤ 1, patient pain visual analog scale [VAS] ≤ 15, patient
global VAS ≤ 20, HAQ-DI ≤ 0.5, tender entheseal points ≤ 1).
Long-term safety and tolerability of secukinumab were
assessed by monitoring vital signs, clinical laboratory variables,
and treatment-emergent adverse events (AEs) over time, up to 84
days after the last administration of treatment.
Statistical analysis. Efficacy data are presented using all
observed data at the given time point of analysis based on the
Full Analysis Set (FAS), which included all subjects with at least
one efficacy assessment during the extension. For patients who
discontinued during a specific period, the end-of-treatment visit
(ie, final assessment 4 weeks after last study treatment) was considered the last week of the corresponding period. PASI assessments were conducted for subjects in whom at least 3% of the
body surface area was affected by psoriatic skin involvement at
baseline. Dactylitis/enthesitis assessments are presented among
patients with dactylitis/enthesitis at baseline. Analysis is presented
in a descriptive manner through week 260.
Graphical representation (line plots) of ACR20, ACR50,
and ACR70 response over time are provided for patients initially randomized to the 150-mg dose. Sankey-style bar charts
for the ACR and PASI responses for all patients (including
patients who were initially randomized to placebo followed by
secukinumab 150 mg) that escalated from 150 to 300 mg and
had efficacy assessments at both up to 32 and up to 56 weeks
after escalation were also drawn from the observed data. The

236 patients in the FAS entered
the extension phase in the
secukinumab 150 mg groupa

3rd year of
treatment

4th year of
treatment

8 Discontinued

• Lost to follow-up (n=1)
• Physician decision (n=2)
• Technical problems (n=2)
• Subject/guardian decision (n=3)

21 Discontinued

• Adverse event (n=5)
• Lack of efficacy (n=1)
• Lost to follow-up (n=2)
• Pregnancy (n=1)
• Subject/guardian decision (n=11)
• Death (n=1)

5th year of
treatment

193 patients completed
5 years of treatment

Figure 1. Patient disposition during the extension phase.
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of treatment, with 86 of 236 (36.4%) patients having escalated to
300 mg; of these 193 patients, 149 (77.2%) were TNF-naïve.

Sankey-style overlay presents ACR and PASI responses using
mutually exclusive definitions.
The safety set included all patients who took at least one
dose of study treatment during the treatment period in the core
or extension study. Evaluation of AEs is based on the secukinumab dose taken prior to the AE and presented as exposure-adjusted incidence rates (EAIRs) per 100 patient-years over
the entire treatment period for each treatment dose and overall.
If a patient experienced an AE after dose escalation, the patient
was counted at the escalated dose.

Disease activity assessed by ACR responses. The
ACR20/50/70 responses reported during the core study for the
group of patients who were originally randomized to secukinumab 150 mg were sustained through 5 years (Figure 2) with
responses of 67.9%/52.7%/37.4% at 5 years. ACR responses
were similar in the secukinumab 150 mg group that included
patients who switched from placebo at week 16 or 24 (Table 2).
ACR response rates achieved in the core study were sustained
through 5 years in both anti–TNF-naïve and anti–TNF-IR groups,
with generally higher responses observed in anti–TNF-naïve patients
across the entire treatment period (Figure 2). ACR responses were
generally similar regardless of whether patients were receiving concomitant methotrexate or not (Supplementary Table 1).

RESULTS
Baseline characteristics and subject disposition.
Baseline demographics and disease characteristics for patients
in the secukinumab 150-mg FAS group (including patients who
switched from placebo to secukinumab 150 mg) are shown in
Table 1. The patient retention rates in this 5-year study were high,
with over 80% of patients who entered the extension study completing the full treatment period (Figure 1). Of the 236 FAS patients
in the secukinumab 150-mg group, 193 (81.8%) completed 5 years

Percentage of responders
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Disease remission/LDA based on DAS28-CRP. The
proportions of patients who achieved disease remission and
LDA states according to DAS28-CRP in the secukinumab
150-mg group (including those who switched from placebo

Full Analysis Set
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Figure 2. ACR20/50/70 responses up to 5 years in the secukinumab 150-mg group. To show the full 5-year efficacy, results are shown for
the group of patients who were originally randomized to secukinumab 150 mg during the core study and entered the extension study in the
secukinumab 150 mg group; patients who switched from placebo to secukinumab 150 mg at weeks 16 and 24 are not included in these
figures. ACR 20/50/70, American College of Rheumatology criteria for 20%/50%/70% improvement in disease activity.

22

MEASE ET AL

|

Table 2. Summary of efficacy results during the extension phasea
Secukinumab 150 mg (N = 236)
Efficacy Endpoints
ACR20
ACR50
ACR70
PASI 75d
PASI 90d
Resolution of dactylitise
Resolution of enthesitisf
DAS28-CRP remission
DAS28-CRP LDA
Minimal Disease Activity
HAQ-DI
BL (SD)

SF-36 PCS

mean change from
BL (SD)
BL (SD)
mean change from
BL (SD)

b

Year 2

Year 3b

Year 4b

Year 5c

158/213 (74.2)
99/213 (46.5)
58/213 (27.2)
93/117 (79.5)
73/117 (62.4)
92/107 (86.0)
96/130 (73.8)
101/213 (47.4)
128/213 (60.1)
76/215 (35.3)
1.12 (0.661)
[n = 213]
−0.40 (0.587)
[n = 213]
38.39 (7.929)
[n = 207]
5.72 (7.893)
[n = 207]

168/229 (73.4)
122/229 (53.3)
71/229 (31.0)
95/127 (74.8)
72/127 (56.7)
106/121 (87.6)
106/137 (77.4)
116/229 (50.7)
149/229 (65.1)
79/232 (34.1)
1.14 (0.671)
[n = 229]
−0.39 (0.632)
[n = 229]
38.15 (7.80)
[n = 230]
5.43 (8.417)
[n = 230]

142/211 (67.3)
103/211 (48.8)
64/211 (30.3)
86/120 (71.7)
68/120 (56.7)
102/113 (90.3)
94/123 (76.4)
111/212 (52.4)
143/212 (67.5)
82/216 (38.0)
1.13 (0.662)
[n = 210]
−0.37 (0.644)
[n = 210]
38.19 (7.734)
[n = 213]
5.52 (8.350)
[n = 213]

137/193 (71.0)
100/193 (51.8)
70/193 (36.3)
83/103 (80.6)
69/103 (67.0)
93/99 (93.9)
89/113 (78.8)
118/194 (60.8)
147/194 (75.3)
77/195 (39.5)
1.09 (0.650)
[n = 193]
−0.39 (0.626)
[n = 193]
38.39 (7.811)
[n = 192]
6.04 (8.341)
[n = 192]

Abbreviation: ACR, American College of Rheumatology; BL, baseline; DAS28-CRP, Disease Activity Score 28-joint count
C-reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; LDA, low disease activity; M, The total number
of patients evaluated in the treatment group; PASI90, 90% improvement in Psoriasis Area and Severity Index; SF-36 PCS,
Short Form-36 Physical Component Summary.
a
Results are n/M (%) unless otherwise stated. Results are shown for patients who entered the extension phase in the secukinumab 150-mg group, including patients who switched from placebo to secukinumab 150 mg at weeks 16/24.
b
All patients received secukinumab 150 mg.
c
Includes 83 patients who had dose escalation from 150 to 300 mg based on physician’s judgement from week 156 onward.
d
Patients with psoriasis affecting ≥3% body surface area at baseline (n = 89 [150 mg] and 82 [75 mg]).
e
Patients (n = 83 [150 mg] and 77 [75 mg]) with dactylitis at baseline, as measured using the Leeds Dactylitis Index.
f
Patients (n = 99 [150 mg] and 91 [75 mg]) with enthesitis at baseline, as measured using the Leeds Enthesitis Index.

to secukinumab 150 mg) at 2 years during the core study
improved yearly through 5 years (Table 2). At 5 years, 60.8% and
75.3% of patients in the secukinumab 150-mg group achieved
DAS28-CRP disease remission and LDA states, respectively.
Resolution of enthesitis and dactylitis. Resolution of
dactylitis and enthesitis achieved with secukinumab 150 mg up to
2 years were sustained through 5 years, with 93.9% and 78.8% of
patients achieving complete resolution of dactylitis and enthesitis,
respectively, at 5 years (Table 2).
Efficacy across other endpoints. Efficacy responses
reported during the core study with secukinumab 150 mg
were also sustained throughout the extension study for the
following parameters: PASI90 and PASI75, HAQ-DI response,
SF-36 PCS, and MDA (Table 2). At 5 years, high PASI75
(80.6%) and PASI90 (67.0%) responses were observed, and
MDA response was 39.5% (Table 2).
Efficacy following dose escalation. The majority of
patients showed improvements in their ACR and PASI responses
after dose escalation from 150 to 300 mg (Figure 3). Lower proportions of patients were ACR nonresponders (fewer than 20)
after escalation from 150 to 300 mg at 12 to 32 weeks (40 of 126
patients, 31.7%) and 36 to 56 weeks (35 of 126 patients, 27.8%)

compared with before escalation (54 of 126, 42.9%). Responses
for higher hurdle ACR endpoints (ACR50 and ACR70) were
achieved by greater proportions of patients at 12 to 32 weeks (55
of 126 patients, 43.7%) and 36 to 56 weeks (64 of 126 patients,
50.8%) after escalation from 150 to 300 mg compared with before
dose escalation (40 of 126 patients, 31.7%) (Figure 3). At 5 years
in the secukinumab group (including patients who switched from
placebo to secukinumab 150 mg), ACR20/50/70 responses were
71.8%/51.8%/39.1%, respectively, in those receiving 150 mg (n
= 110) and 69.9%/51.8%/32.5%, respectively, in those who had
escalated to 300 mg (n = 83).
Similarly, lower proportions of patients were PASI nonresponders (less than 50) after escalation from 150 to 300 mg at
12 to 32 weeks (9 of 80 patients, 11.3%) and 36 to 56 weeks (7
of 80 patients, 8.8%) compared with those before escalation (16
of 80, 20.0%). Responses for the high hurdle endpoint PASI90
were achieved by greater proportions of patients at 12 to 32
weeks (38 of 80 patients, 47.5%) and 36 to 56 weeks (47 of
80 patients, 58.8%) after dose escalation compared with before
escalation (27 of 80 patients, 33.8%). At 5 years in the secukinumab group (including patients who switched from placebo to
secukinumab 150 mg), PASI75/PASI90 responses were 86.3%
and 78.4%, respectively, in those receiving 150 mg (n = 51) and
75.0% and 55.8%, respectively, in those who had escalated to
300 mg (n = 52).
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Safety. Safety is reported as EAIR/100 patient-years for
all patients (N = 587) who were administered at least one dose
of study treatment during the core or the extension study.
The type, incidence, and severity of AEs over the 260-week
treatment period were consistent with those reported at year
1 and year 2. The EAIR of AEs and serious AEs observed with
secukinumab are shown in Table 3. The majority of AEs with
the highest EAIRs were infections usually involving the upper
respiratory tract (EAIR = 8.0 for any dose of secukinumab),
whereas the most common AE was nasopharyngitis (EAIR =
8.6 for any dose of secukinumab).
ACR Response
100
15%

Percentage (%)

80
60

25%

17%
18%
25%
25%

40
20
0

26%

43%

Before Up-titration

25%

21%

32%

28%

12 to 32 weeks

36 to 56 weeks

ACR <20 (No Response)

20 ≤ ACR <50

50 ≤ ACR <70

ACR ≥70

PASI Response
100

Percentage (%)

80
60
40

34%

48%

59%

23%
25%
24%

20

16%
20%

16%

11%

9%

12 to 32 weeks

36 to 56 weeks

0
Before Up-titration

16%

PASI <50 (No Response)

50 ≤ PASI <75

75 ≤ PASI <90

PASI ≥90

Figure 3. American College of Rheumatology (ACR) and
Psoriasis Area and Severity Index (PASI) responses up to 56 weeks
after dose escalation from 150 to 300 mg. Before escalation is
defined as the last assessment done on or before patient took the
escalated dose. Patients who entered the extension phase in the
secukinumab 150-mg group (including patients who switched from
placebo to secukinumab 150 mg at weeks 16 and 24) and who had
both pre- and all postdose escalation assessments data available
are included in the analysis for ACR (n = 126) and PASI (n = 80)
responses.
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Table 3.

period

23

Safety summary across the entire 260-week treatment

a

Category
Exposure to treatment – d, mean (SD)
Death, n (%)
Discontinued due to AEs, n (%)
Any AE
Serious AEs
Most Common AEs
Nasopharyngitis
Upper respiratory tract infection
AEs of special interest
Serious infections
Candida infections
Crohn's disease
MACE
Malignancies

Any Secukinumab
Dose (N = 587)
1443.6 (616.7)
6 (1.0)
49 (8.3)
126.7
7.5
8.6
8.0
1.8
0.9
0.2
0.5
0.8

Abbreviation: AE, adverse event; EAIR, exposure-adjusted incidence
rate; MACE, major adverse cardiac event.
a
Data are EAIR, unless otherwise stated.

Six deaths were reported during this 5-year study. Two
of these deaths occurred during the core study: one died of
stroke/cerebrovascular accident (a patient receiving secukinumab 75 mg), and one died of myocardial infarction (a patient
receiving secukinumab 150 mg); but the other four deaths
occurred during the extension phase: one patient receiving
secukinumab 75 mg died from squamous cell carcinoma of
the pharynx, the other three patients, in the secukinumab 150mg group, died from acute myocardial infarction, cardiac failure, and septic shock, respectively.
The EAIR for Crohn’s disease was 0.2 for the entire 5-year
period. Confirmed cases of Crohn’s disease were reported during
the core study for one patient in the secukinumab 75-mg group
(23-year-old male with no history of IBD; the event was graded
as severe and the patient discontinued; the investigator did not
suspect a relationship to study treatment) and one patient in the
placebo group (exacerbation). One additional confirmed case
of Crohn’s disease was reported for one patient in the secukinumab 75-mg group during the extension study (68-year-old
male with no history of IBD; the event was graded as moderate
in severity and the patient remained in the study; the investigator
did not suspect a relationship to study treatment).
The EAIR for Candida infections was 0.9 for patients
treated with any dose of secukinumab during the entire treatment period. The infections were located in the skin and
mucus membranes, none were systemic or invasive, and all
except one were nonserious, mild, or moderate in severity,
responded to standard therapy, and did not lead to study
treatment discontinuation. The EAIR for malignancies was 0.8
for patientss treated with any dose of secukinumab during the
entire treatment period.
Overall, the incidence of treatment-emergent antidrug antibodies (ADAs) was low (detected in eight patients) throughout the
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5-year period; three patients were positive at baseline and continued to show ADAs, and two patients showed neutralizing antibodies at week 24. A clear relationship between ADA formation
and deviating pharmacokinetics or immunogenicity-related AEs
was not observed.

DISCUSSION
Secukinumab demonstrated sustained improvements in
the signs and symptoms, function, and health-related quality of life in patients with active PsA. The patient retention
rates in this study were high, with over 80% of patients who
entered the extension study completing the full 5-year treatment period. These are the first 5-year findings reported for
secukinumab in PsA, and the data add to the growing body
of evidence supporting the use of IL-17 inhibitors for the treatment of PsA as recognized in the guidelines from the EULAR
(8), GRAPPA (11), and recently the ACR/National Psoriasis
Foundation (NPF) (19).
This robust study also provides data on the benefits of dose
escalation in patients whose symptoms are inadequately controlled on 150 mg. Improvement in ACR and PASI responses was
achieved in patients who escalated from secukinumab 150 to 300
mg, indicating a benefit of dose escalation in patients who require
additional control of symptoms. In agreement with previous studies
(3,8,9,11,13–16), secukinumab treatment in FUTURE 1 was shown
to be efficacious in both anti–TNF-naïve and anti–TNF-IR patients,
with clinical responses generally higher in anti–TNF-naïve patients
than in anti–TNF-IR patients. These results support the effectiveness
of long-term treatment with secukinumab for biologic-naïve patients
as well as for patients who have previously failed anti-TNF therapy.
The safety profile of secukinumab was consistent with
that previously reported for PsA (3,9,12–17) and psoriasis
(6). No new or unexpected safety signals were observed in
patients with PsA over a treatment period of up to 5 years.
The rates of Candida infections, major adverse cardiac events,
and malignancies reported were low throughout the 5-year
treatment period and consistent with results of an analysis of
long-term safety of secukinumab in patients with psoriasis,
PsA, and ankylosing spondylitis (20). The low rate of Crohn’s
disease reported in the study is in line with findings of a recent
retrospective analysis of 21 clinical trials of psoriasis, PsA,
and ankylosing spondylitis, which found that IBD events were
uncommon with secukinumab treatment (21). It should be
noted that patients with active ongoing inflammatory disease
were excluded from this study, so patients with a history of IBD
were likely not enrolled.
Limitations of this study included a lack of a long-term comparator due to the fact that long-term treatment with placebo is
considered unethical; the placebo-controlled period of the core
trial was, therefore, only up to week 16. There was no active
comparator included, and results could be potentially biased

as patients remaining in the study are those patients benefiting
from secukinumab. Although efficacy responses in the current
study were sustained irrespective of previous anti-TNF exposure,
patients eligible for inclusion in this study could have been treated
with no more than three anti-TNF agents; this may be viewed as
a limitation of the study. The inclusion of patients in this extension study based on the investigator’s judgement of their overall
response to therapy likely resulted in a population of preselected
responders.
Results from this long-term extension study confirm the
benefit of IL-17 inhibition with secukinumab for sustained
improvements in the signs and symptoms of major clinical
domains of PsA. With no new safety concerns over a treatment period of up to 5 years, results from the 5-year phase III
FUTURE 1 study support the long-term efficacy, safety, and
tolerability of secukinumab in the treatment of patients with
PsA.
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